Royal Fund Management LLC Takes Position in Eli Lilly and Company (NYSE:LLY)

Royal Fund Management LLC bought a new stake in Eli Lilly and Company (NYSE:LLY) in the 4th quarter, according to its most recent 13F filing with the SEC. The firm bought 367 shares of the company’s stock, valued at approximately $214,000.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in LLY. Simon Quick Advisors LLC lifted its stake in shares of Eli Lilly and Company by 10.5% in the fourth quarter. Simon Quick Advisors LLC now owns 2,927 shares of the company’s stock valued at $1,706,000 after buying an additional 278 shares in the last quarter. Clear Harbor Asset Management LLC bought a new stake in Eli Lilly and Company during the fourth quarter valued at approximately $363,000. Terril Brothers Inc. grew its holdings in Eli Lilly and Company by 113.2% in the 4th quarter. Terril Brothers Inc. now owns 808 shares of the company’s stock worth $471,000 after acquiring an additional 429 shares during the last quarter. Hartline Investment Corp grew its holdings in Eli Lilly and Company by 1.1% in the fourth quarter. Hartline Investment Corp now owns 21,934 shares of the company’s stock worth $12,786,000 after purchasing an additional 248 shares during the period. Finally, Commonwealth Equity Services LLC boosted its holdings in Eli Lilly and Company by 5.2% in the fourth quarter. Commonwealth Equity Services LLC now owns 354,565 shares of the company’s stock worth $206,683,000 after purchasing an additional 17,461 shares during the last quarter. 82.53% of the stock is owned by institutional investors.

Eli Lilly and Company Price Performance

LLY traded down $20.94 during trading on Friday, reaching $734.97. The stock had a trading volume of 4,595,138 shares, compared to its average volume of 2,629,045. The stock has a 50 day moving average of $761.06 and a two-hundred day moving average of $671.38. The company has a quick ratio of 0.73, a current ratio of 1.35 and a debt-to-equity ratio of 1.90. The firm has a market capitalization of $698.52 billion, a price-to-earnings ratio of 108.24, a price-to-earnings-growth ratio of 1.50 and a beta of 0.37. Eli Lilly and Company has a 1-year low of $419.80 and a 1-year high of $800.78.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings data on Tuesday, April 30th. The company reported $2.58 EPS for the quarter, topping analysts’ consensus estimates of $2.53 by $0.05. Eli Lilly and Company had a return on equity of 56.98% and a net margin of 17.08%. The company had revenue of $8.77 billion for the quarter, compared to the consensus estimate of $8.94 billion. During the same quarter in the previous year, the business earned $1.62 EPS. The company’s quarterly revenue was up 26.0% compared to the same quarter last year. As a group, equities analysts anticipate that Eli Lilly and Company will post 13.83 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on LLY. DZ Bank cut shares of Eli Lilly and Company from a “buy” rating to a “hold” rating and set a $820.00 price target for the company. in a research report on Wednesday, February 21st. Cantor Fitzgerald reissued an “overweight” rating and issued a $885.00 price objective (up from $815.00) on shares of Eli Lilly and Company in a report on Tuesday. The Goldman Sachs Group increased their price objective on shares of Eli Lilly and Company from $650.00 to $723.00 and gave the company a “neutral” rating in a research note on Thursday, April 11th. Wells Fargo & Company increased their price target on Eli Lilly and Company from $700.00 to $825.00 and gave the company an “overweight” rating in a report on Tuesday, February 6th. Finally, BMO Capital Markets boosted their price target on shares of Eli Lilly and Company from $900.00 to $1,001.00 and gave the company an “outperform” rating in a report on Wednesday. Three equities research analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $757.95.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.